Generate Biomedicines Inc's Quiet Period To End on April 8th (NASDAQ:GENB)

Key Points

• Quiet period ends April 8: Generate Biomedicines' IPO quiet period expires on April 8, after which underwriters and IPO insiders can resume issuing research and forecasts and brokerages that underwrote the deal will likely initiate coverage.
• IPO size and timing: The company issued 25,000,000 shares in its public offering on February 27 in a $400,000,000 deal priced at $16.00 per share.
• Analyst sentiment — Moderate Buy: Five analysts rate the stock Buy and one rates it Hold, yielding a consensus of “Moderate Buy” with an average price target of $25.00 (notable targets: Guggenheim $30, Piper Sandler $24).

Generate Biomedicines' (NASDAQ:GENB - Get Free Report) quiet period will expire on Wednesday, April 8th. Generate Biomedicines had issued 25,000,000 shares in its public offering on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Guggenheim initiated coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a "buy" rating and a $30.00 price target on the stock. Zacks Research upgraded Generate Biomedicines to a "hold" rating in a report on Wednesday, March 25th. Wall Street Zen upgraded Generate Biomedicines to a "hold" rating in a research note on Saturday, March 14th. Cantor Fitzgerald initiated coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set an "overweight" rating on the stock. Finally, Piper Sandler started coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an "overweight" rating and a $24.00 price target for the company. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $25.00.

Generate Biomedicines Stock Performance

NASDAQ:GENB opened at $12.50 on Wednesday. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.